قالب وردپرس درنا توس
Home / Insurance / San Francisco reaches $ 58 million opioid deal with Teva, Allergan

San Francisco reaches $ 58 million opioid deal with Teva, Allergan



(Reuters) – Teva Pharmaceutical Industries Ltd. and AbbVie Inc.’s Allergan unit reached a $ 58 million deal with the city of San Francisco on Tuesday just before the conclusion of a lawsuit over allegations that they incited an opioid epidemic in the city.

Under the agreement announced by city prosecutor David Chiu, Israel-based Teva will pay $ 25 million in cash and contribute $ 20 million of the drug Narcan to recover from overdoses. AbbVie will pay $ 13 million.

“This will provide significant resources to help with education, prevention and treatment, and the addition of tens of millions of dollars of overdose medication will save lives in the Bay Area,”

; said Paul Geller, a lawyer who represented the city in the negotiations. the settlement.

Teva’s settlement also resolves the city’s claim against the drug distributor Anda Inc, which is owned by Teva.

San Francisco will receive $ 54 million, while $ 4 million will go to attorneys’ fees.

“Today’s settlement is another important step forward in providing life – saving treatments to people suffering from opioid dependence,” Teva said in a statement. AbbVie did not immediately respond to a request for comment.

The settlement was reached before the closing arguments in a trial that began on April 25. San Francisco will continue with closing arguments on Tuesday against the pharmacy chain Walgreens, the last remaining defendant in the case.

The parent company Walgreens Boots Alliance Inc. has denied the crime. Teva and Allergan did not acknowledge crime as part of the deal.

San Francisco accused Walgreens, Teva, Allergan and Anda of creating a “general nuisance” by flooding the city with prescription opioids and failing to prevent the drugs being diverted for illegal use.

The companies claimed that they were selling legal drugs prescribed by doctors.

The lawsuit was selected as a time against drug manufacturers, distributors and pharmacies, and tested the strength of claims in thousands of lawsuits filed by state and local authorities. In other similar trials, drug manufacturers have also been accused of toning down the risks of substance abuse and overdose in the marketing of their painkillers.

San Francisco has been hit hard by the opioid crisis, which has caused more than 500,000 deaths in overdoses across the country over the past two decades, according to US data. Opioid-related health problems account for 25% of visits to the emergency department at the city’s largest public hospital, according to a court document at the beginning of the trial.

San Francisco’s lawsuit, filed in 2018, originally included claims against drug manufacturers Purdue Pharma LP, Johnson & Johnson and Endo International PLC, and the three largest U.S. drug distributors – McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp.

The city settled with the defendants before the trial. It signed a nationwide $ 26 billion deal with J&J and the drug distributors and agreed to support Purdue Pharma’s bankruptcy plan.

Teva has tried to reach a nationwide agreement on its opioid responsibility.

Teva’s CEO Kare Schultz said on May 3 that the company expects to reach a nationwide agreement by the end of 2022 and pay about $ 2.6 billion over 15 years.


Source link